sali pic6

SALITEST - saliva cancer 


sali pic5

Cancer in the 1st stage is curable in more than 95% of cases.

Salitest is an oncology test using saliva to determine 10 kinds of cancer in the early stages, thereby giving a unique opportunity to save the lives of hundreds of thousands of people worldwide every year.

By 2020, world population will exceed 8 billion people, and according to statistics every hundredth inhabitant of the Earth will be diagnosed with cancer!

Oncological diseases are dangerous because in the initial stages are asymptomatic, and the person is unaware of the early development of cancer. And on the next stages of cancer symptoms are similar to symptoms of many diseases - it's called "clinical symptoms mask." The problem of modern medicine lies in determining the presence of cancer at an early stage where it is treatable.

How does Salitest work?

Analysis of the presence of cancer by Salitest is built on a proven difference of metabolism of malignant and healthy cells. If there is a tumor in the body, there is also a change of parameters of body fluids, including saliva. Salitest is based on the definition of 30 biological tumor markers in saliva and simultaneous analysis of their quantities using unique algorithms.

    Laboratory test has two steps:

  • Biological analysis of 30 parameters of saliva in a specialized laboratory;
  • The mathematical analysis of the data (concentrations of 30 parameters) and the patient's history - giving a diagnosis.

sali pic

Why Salitest is necessary for everyone?

Salitest is a patented technology developed by Russian (Omsk Oncology Center) and French (University of Strasbourg) oncologists. Unlike to existing tests for susceptibility to cancer, which show the theoretical probability of cancer in future, Salitest gives clear answers to questions about your current status:

  • Whether you have early signs of cancer;
  • If so, which part of the body are they located.

sali pic2

Why do we use saliva?

The blood is not suitable for early detection of malignant tumors, because one of the blood functions is homeostatic, in relation to which blood has biochemical changes only if significant changes in the body already present (late stages of cancer).

Saliva is not regulated homeostatically so its biochemical composition varies considerably, even for small pathologies. These changes may indicate that the body has beginning of life threatening processes. Furthermore, due to the characteristics of the blood is impossible to determine some biochemical markers, using saliva is possible.

That is why the analysis of saliva is taken, which gave the name to the test - Salitest.

sali pic3

sali pic4

Which types of cancer is possible to check?

The main know-how of the test is the algorithm of data processing, which allows you to simultaneously analyze a large number of specified parameters - oncomarkers.

Salitest allows you to define the early stages of cancer of the following organs:

  • lungs;
  • intestine;
  • prostate;
  • breast;
  • thyroid;
  • kidney;
  • cervix and uterine body;
  • stomach;
  • bladder;
  • ovary.

Scientific consultants of Salitest:

  Victor Kosenok

  Professor, Doctor of Medical Sciences, Academician of the Academy of Medical and Technical Sciences of Russia, Chief oncologist of Omsk Region

   Gilbert Massard

   Professor, Doctor of Medical Sciences, Academician, Head of thoracic surgery clinic of the University of Strasbourg (France)




How to buy Salitest?

Currently, Salitest is sold only in Russia and the analysis is carried out in the laboratory in Omsk (Siberia). But we are confident that in the next 2-3 years this test will be available to residents of most countries in the world.

We welcome strategic partners and investors for fast commercialization of Salitest on a global scale to share our success!



  • project in a high stage of readiness;
  • fully equipped laboratory in Omsk, Russian Federation (etalon laboratory);
  • 4000 tests per month - the capacity of the existing equipment;
  • 10,000 tests done as clinical study;
  • up to 97% - diagnostic accuracy of 10 types of cancer;
  • Scientific support: Omsk Oncology Center (Russian Federation), University of Strasbourg (France);
  • system of express-delivery from Moscow and St. Petersburg to laboratory in Omsk is tested and works normally without influence to the quality of results (terms of delivery, storage, different temperature conditions are tested);
  • the potential demand only by Omsk Oncology Center is about 80-100 tests per day and completely covers the possibility of 1 laboratory at 70-80%.


  • a non-invasive method;
  • the highest precision among the existing methods - up to 97%;
  • coverage of more than 80% of cancers (10 types of cancer with the addition of 4 more types in 2 years);
  • the possibility of the diagnosis in the early asymptomatic stages;
  • high speed of the test (2-4 hours in the laboratory);
  • low test value (proteins are not used in the analysis).


  • oncology centers, clinics and hospitals;
  • health insurance companies (discount on the insurance policy with a negative test result);
  • pharmacy chains (selected pharmacies in conjunction with oncologists at hospitals);
  • state programs on the clinical examination of certain population groups;
  • programs on the clinical examination of employees of corporations, etc.;
  • sales through pharmacies and convenience stores for health and medical equipment in conjunction with family doctors.

MARKET VOLUME is more than $ 0.5 billion per year, or 2% of the population of Earth per year.

Current capitalization of the project - 22 million dollars.

We offer the following variants of cooperation:

  • Sale of the part of the company to a strategic investor and common development of the project in the global market using opportunities and pharmaceutical channels of investor;
  • Sale of a minority share to investor in order to further finance of clinical tests, CE and FDA certification;
  • Franchise: exclusive distribution and construction of laboratories in your area with a fixed payment for each sold test.


  • "Blind test" - an investor may bring an agreed number of tubes with the saliva of patients of any hospital and get the diagnosis or conclusion about the presense or absence of the disease for each tube with the overall accuracy of the test close to 100%;
  • "Blind test" in Omsk Oncology Center - investor collect saliva of incoming patients, then mixes the tubes, gives to the laboratory and receives result with overall accuracy of the test close to 100%.